Moderna Files FDA Application for the JN.1 Targeting COVID-19 …
WEBJun 7, 2024 · Manufacturing is underway and doses of Moderna's Spikevax 2024-2025 formula will be ready to ship as early as August, pending regulatory approval CAMBRIDGE, MA / ACCESSWIRE / June 7, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for review of its Spikevax 2024-2025 formula, targeting the SARS-CoV-2 variant ...
Moderna R&D Day Highlights Progress and Strategic Priorities
WEBSep 12, 2024 · Moderna R&D Day Highlights Progress and Strategic Priorities. Focuses on ten product approvals through 2027. Expects to submit next-generation COVID vaccine for approval in 2024. Expects to submit flu/COVID combination vaccine for approval in 2024. Announces positive Phase 3 results for its RSV vaccine for high-risk adults aged 18 to 59 ...
News Details - Moderna
WEBMar 27, 2024 · Announces positive clinical trial data from three new vaccines against viruses that cause significant burden (Epstein-Barr virus, Varicella-Zoster virus, norovirus) and advances programs toward Phase 3 development. Anticipates U.S. launch of vaccine against RSV following FDA approval and ACIP recommendation in 2024.
Combined COVID–flu vaccines are coming: Moderna jab clears
WEBJun 28, 2024 · Moderna is now planning to seek approval from the US Food and Drug Administration (FDA) to bring the vaccine to market. Combination vaccines can have big public-health benefits, but they are...
News Details - Moderna
WEBJun 3, 2024 · mRNA-4157 (V940) is a novel investigational messenger RNA (mRNA)-based individualized neoantigen therapy (INT) consisting of a synthetic mRNA coding for up to 34 neoantigens that is designed and produced based on the unique mutational signature of the DNA sequence of the patient's tumor.
Moderna and Merck Announce mRNA-4157/V940, an …
WEBDec 13, 2022 · mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a statistically significant and clinically meaningful reduction in the risk of disease recurrence or death compared to KEYTRUDA monotherapy in stage III/IV melanoma patients with high risk of recurrence following complete resection Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a ...
Moderna Says Its Booster Significantly Raises Antibodies …
WEBDec 20, 2021 · A booster shot of the Moderna coronavirus vaccine significantly raises the level of antibodies that can thwart the Omicron variant, the company announced on Monday.
Moderna R&D day: $1 billion in cost cuts, 10 product launches
WEBSep 12, 2024 · Moderna on Thursday said it plans to cut around $1.1 billion in expenses by 2027 and win approvals for several new products as it charts a path forward after the rapid decline of its Covid...
Moderna says Covid-flu combination vaccine shows positive …
WEBJun 10, 2024 · Vaccine maker Moderna announced positive late-stage trial results for its Covid-flu combination vaccine. There could be a combined Covid-19 and flu shot in our future, although it won’t be ready...
Moderna says its RSV shot is 50% effective across a second season
WEBNEW YORK, June 26 (Reuters) - Moderna Inc (MRNA.O) respiratory syncytial virus (RSV) shot mRESVIA showed 50% efficacy in preventing RSV after 18 months, the drugmaker said on Wednesday.